NTRK1 and cancer: Nevertheless, enzymes as cancer biomarkers have profound clinical utilities in the personalized approach to cancer diagnosis and treatment: Her-2/neu, a cell membrane surface-bound receptor tyrosine kinase, is a predictive marker to select breast cancer patients for treatment with trastuzumab (Herceptin)[2,3].